Am J Transplant, Volume 21, Suppl 3 Archives - Page 132 of 139 - ATC Abstracts

2021 American Transplant Congress
Predicting Post-transplant Death and Graft Loss Risk: Insight at Listing
N. Dzebisashvili¹, M. Schnitzler², K. Lentine², K. Venkataramani¹, S. Ghosh¹
¹CareDx, Brisbane, CA, ²Saint Louis University, St. Louis, MO
*Purpose: Prognostication models for post-transplant outcomes deriving inputs from information collected on donor (DDR/LDR), candidate (TCR) and transplant recipient (TRR) registrations can provide useful information…
2021 American Transplant Congress
Impact of COVID-19 on Solid Organ Transplantation
E. Sampson¹, S. Hall², K. Robichaux³, A. Kumar², N. Kemmer⁴, J. Buggs⁵
¹Lake Erie College of Osteopathic Medicine, Tampa, FL, ²Morsani College of Medicine, University of South Florida, Tampa, FL, ³Honors College, University of South Florida, Tampa, FL, ⁴Transplant Hepatology, Tampa General Hospital, Tampa, FL, ⁵Transplant Surgery, Tampa General Hospital, Tampa, FL
*Purpose: Patterns of racial disparities have been identified throughout the history of American medicine. In December 2019, COVID-19 was first detected and has had a…
2021 American Transplant Congress
Kidney Transplantation Alone in Patients with Compensated Cirrhosis: A Multicenter Study
A. Kassem¹, S. Asrani¹, S. W. Biggins², Y. Darwish¹, M. Nadim³, B. Fischbach¹, T. Fong³
¹Baylor University Medical Center at Dallas, Dallas, TX, ²University of Washington, Seattle, WA, ³USC - Keck, Los Angeles, CA
*Purpose: Patients undergoing kidney transplant (KTA) often have risk factors for liver disease including viral hepatitis and non-alcoholic fatty liver disease (NAFLD). Recent European Association…
2021 American Transplant Congress
De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience
N. Singh¹, T. Le¹, M. S. Naseer¹, S. Asmil¹, A. Palermini¹, A. Qamar¹, R. Chand¹, S. Tandukar¹, D. Aultman², H. Shokouh-Amiri², G. Zibari²
¹Transplant, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA, ²Advanced Surgery, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA
*Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…
2021 American Transplant Congress
Mapping Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI) in Kidney Transplant Biopsies Reveals Two Classes of Early AKI That Differ in Their Response-to-Wounding
P. Halloran¹, J. Reeve¹, G. Böhmig², O. Viklicky³, M. Myslak⁴, G. Gupta⁵, &. the INTERCOMEX Study Group⁶
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²Medical University of Vienna, Vienna, Austria, ³Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ⁴Pomeranian Medical University, Szczecin, Poland, ⁵Virginia Commonwealth University, Richmond, VA, ⁶., ., AB, Canada
*Purpose: We recently analyzed injury-induced molecular changes in kidney transplant biopsies using principal component analysis (PCA) (AJT https://doi.org/10.1111/ajt.16374). PC1 reflected all injury, PC2 distinguished early…
2021 American Transplant Congress
Pregnancy Outcomes in 39 Lung Transplant Recipients
S. Constantinescu¹, L. A. Coscia², A. Yusuf², S. Rao³, M. J. Moritz⁴
¹Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ²Transplant Pregnancy Registry International, Philadelphia, PA, ³University of Virginia Heath System, Charlottesville, VA, ⁴Lehigh Valley Health Network, Allentown, PA
*Purpose: The purpose of this study is to describe 52 pregnancies in 39 lung transplant recipients reporting to the Transplant Pregnancy Registry International (TPRI) from…
2021 American Transplant Congress
Tacrolimus Therapeutic Exposure is Not Consistently Predicted by Target Troughs or CYP3A5 Variants in Stable Renal Transplant Recipients
K. Tornatore¹, K. Attwood², D. Brazeau³, B. Murray⁴
¹Pharmacy Practice, School of Pharmacy; University at Buffalo, Buffalo, NY, ²Biostatistics, School of Public Health; University at Buffalo, Buffalo, NY, ³Pharmacy Practice, School of Pharmacy; Marshall University, Huntington, WV, ⁴Medicine, Erie County Medical Center Corp., Buffalo, NY
*Purpose: Tacrolimus (TAC) immunosuppression requires therapeutic trough monitoring post-transplant due to notable interpatient pharmacokinetic(PK) variability which may be attributed to CYP3A5 polymorphisms. We investigated the…
2021 American Transplant Congress
Overall Survival by Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant
S. Prockop¹, L. Gamelin², R. Dinavahi², Y. Sun², N. Guzman-Becerra², H. Parmar²
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Atara Biotherapeutics, South San Francisco, CA
*Purpose: Tabelecleucel is an investigational, off-the-shelf, allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy being studied in patients (pts) with serious EBV-driven diseases, including post-transplant lymphoproliferative disease…
2021 American Transplant Congress
Blood Type A2/a2b to B Renal Transplantation: A Single Center Retrospective Cohort Study
V. S. Tatapudi, N. Alnazari, R. Chand, N. M. Ali, B. E. Lonze, R. A. Montgomery
NYU Langone Transplant Institute, NYU Langone Health, New York, NY
*Purpose: Blood type B candidates on the deceased donor kidney waitlist have a lower transplantation rate and longer wait time than candidates of other blood…
2021 American Transplant Congress
Outcomes of Abdominal Transplant Recipients Who Receive Organs from Donors with Positive Cultures
A. Perez Cortes Villalobos, A. Humar, D. Kumar
University Health Network, Toronto, ON, Canada
*Purpose: Due to limited organ availability, use of donors with positive bacterial cultures is common practice. One of the main concerns is transmission to the…